World Health Organization Raises Alert Over Critical Scarcity of Weight-Loss Medications
Fewer than 10% of people who could benefit from obesity jabs like Wegovy can access them, caution the World Health Organization as it issues its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to this class of drugs.
Based on projections, over two billion are projected to be obese by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a lifelong illness that can be managed with comprehensive and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and logistical bottlenecks are significant hurdles to universal availability to the injections that can help people shift substantial weight, says the agency.
GLP-1 Therapy Scarcity
Even under the present most favorable case, the supply of GLP-1 therapies might only reach around 100 million people – fewer than 10% of the global need, according to the health organization.
The guideline encourages governments and firms to increase access, by strategies such as voluntary licensing.
The intellectual property rights on a key compound – the primary component of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Work
The injections replicate a biological compound to slow digestion, curb appetite and enhance the sense of being full so users eat less.
People commonly start to lose weight within a few weeks of starting on the once-weekly jabs.
Evidence points to users may put most of the weight back on after a year of halting the drug, as their typical food cravings come back.
Being above a healthy weight increases your risk for contracting health problems, including diabetes, heart disease, stroke, and some cancers.
Excess weight concerns individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, per the WHO.
